Literature DB >> 7507676

Living related liver transplantation across ABO blood groups with FK506 and OKT3.

Y Tokunaga1, K Tanaka, S Fujita, T Yamaguchi, H Sawada, H Kato, S Uemoto, Y Yamaoka, K Ozawa.   

Abstract

In living related liver transplantation (LRLT), the use of graft livers across ABO blood groups is unavoidable since the organ donor is usually one of the recipient's parents. This report presents our initial experiences with LRLT, focusing on ABO-incompatible cases. From June 1990 to May 1992, we successfully performed a series of 34 LRLT on children (15 males and 19 females) ranging in age from 7 months to 15 years. Overall recipient survival rates were 90% (25/28) in elective LRLT and 50% (3/6) in emergency LRLT. These cases were classified into three groups: ABO blood group-identical (n = 21), compatible (n = 10), and incompatible (n = 3). The immunosuppressive regimen consisted of FK506 and low-dose steroids in the first two groups. In the incompatible cases, exchange transfusion was performed to decrease anti-A and/or -B antibody titers before LRLT, and prophylactic OKT3 was added to FK506 and steroids after LRLT. No significant difference in recipient and graft survival was observed among the groups. In the identical group, no rejection episodes have been observed thus far. Rejection occurred in two out of the ten compatible cases. Among the incompatible cases, one recipient had mild rejection and was treated. The remaining two recipients have had no rejection episodes thus far. Although all three recipients had cytomegalovirus (CMV) infection, they were successfully treated with ganciclovir, and no lethal infection has developed in any of these cases. The present results suggest that graft livers from living related donors across ABO blood groups can function well with FK506, low-dose steroids, and prophylactic OKT3 without causing lethal complications.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7507676     DOI: 10.1007/bf00335967

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  5 in total

1.  Liver transplantation: Evading antigens-ABO-incompatible liver transplantation.

Authors:  Ali Zarrinpar; Ronald W Busuttil
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-11-18       Impact factor: 46.802

Review 2.  Management of ABO-incompatible living-donor liver transplantation: past and present trends.

Authors:  Vikram Raut; Shinji Uemoto
Journal:  Surg Today       Date:  2011-02-23       Impact factor: 2.549

Review 3.  Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.

Authors:  M I Wilde; K L Goa
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

Review 4.  Recipient outcomes after ABO-incompatible liver transplantation: a systematic review and meta-analysis.

Authors:  Jian Wu; Sunyi Ye; Xiaofeng Xu; Haiyang Xie; Lin Zhou; Shusen Zheng
Journal:  PLoS One       Date:  2011-01-25       Impact factor: 3.240

Review 5.  Outcomes after liver transplantation in accordance with ABO compatibility: A systematic review and meta-analysis.

Authors:  Eung Chang Lee; Seong Hoon Kim; Sang-Jae Park
Journal:  World J Gastroenterol       Date:  2017-09-21       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.